AU2016209906A1 - PET imaging agents - Google Patents

PET imaging agents Download PDF

Info

Publication number
AU2016209906A1
AU2016209906A1 AU2016209906A AU2016209906A AU2016209906A1 AU 2016209906 A1 AU2016209906 A1 AU 2016209906A1 AU 2016209906 A AU2016209906 A AU 2016209906A AU 2016209906 A AU2016209906 A AU 2016209906A AU 2016209906 A1 AU2016209906 A1 AU 2016209906A1
Authority
AU
Australia
Prior art keywords
methyl
compound
autotaxin
mmol
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016209906A
Other languages
English (en)
Inventor
Yves Auberson
Emmanuelle Briard
Darren Legrand
Berndt Oberhauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2016209906A1 publication Critical patent/AU2016209906A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2016209906A 2015-01-20 2016-01-20 PET imaging agents Abandoned AU2016209906A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105336P 2015-01-20 2015-01-20
US62/105,336 2015-01-20
PCT/IB2016/050276 WO2016116875A1 (en) 2015-01-20 2016-01-20 Pet imaging agents

Publications (1)

Publication Number Publication Date
AU2016209906A1 true AU2016209906A1 (en) 2017-08-03

Family

ID=55300733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016209906A Abandoned AU2016209906A1 (en) 2015-01-20 2016-01-20 PET imaging agents

Country Status (12)

Country Link
US (2) US10450298B2 (enExample)
EP (1) EP3247706B1 (enExample)
JP (2) JP6723264B2 (enExample)
KR (1) KR20170103960A (enExample)
CN (1) CN107406419B (enExample)
AU (1) AU2016209906A1 (enExample)
BR (1) BR112017015455A2 (enExample)
CA (1) CA2974311A1 (enExample)
EA (1) EA201791643A1 (enExample)
ES (1) ES2828715T3 (enExample)
MX (1) MX2017009452A (enExample)
WO (1) WO2016116875A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974311A1 (en) 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents
TWI809597B (zh) * 2020-12-16 2023-07-21 美商美國禮來大藥廠 預靶向造影劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
WO2005043300A2 (en) 2003-10-20 2005-05-12 Empirix, Inc. Computer language interpretation and optimization for server testing
BRPI0510512A (pt) 2004-04-28 2007-10-30 Icos Corp derivados de arilfenilamino, arilfenilamida e sulfeto de arilfeniléter
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
CN101429161A (zh) * 2008-12-05 2009-05-13 常熟理工学院 Pet显像剂前体异喹啉甲酰胺衍生物的合成方法
JP5767205B2 (ja) * 2009-04-02 2015-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オートタキシン阻害剤としての複素環式化合物
US8999974B2 (en) 2010-08-09 2015-04-07 Raqualia Pharma Inc. Acyl piperazine derivatives as TTX-S blockers
JP2013536200A (ja) * 2010-08-20 2013-09-19 アミラ ファーマシューティカルス，インコーポレーテッド オートタキシン阻害剤およびその使用
PT2861566T (pt) * 2012-06-13 2017-02-08 Hoffmann La Roche Novos diazaspirocicloalcanos e azaspirocicloalcanos
CN104968656B (zh) * 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
CA2974311A1 (en) 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents

Also Published As

Publication number Publication date
CN107406419A (zh) 2017-11-28
US20200017474A1 (en) 2020-01-16
US20180273509A1 (en) 2018-09-27
EA201791643A1 (ru) 2017-11-30
EP3247706A1 (en) 2017-11-29
MX2017009452A (es) 2017-11-08
US10450298B2 (en) 2019-10-22
EP3247706B1 (en) 2020-07-08
KR20170103960A (ko) 2017-09-13
ES2828715T3 (es) 2021-05-27
CA2974311A1 (en) 2016-07-28
BR112017015455A2 (pt) 2018-01-23
JP6723264B2 (ja) 2020-07-15
US10865195B2 (en) 2020-12-15
CN107406419B (zh) 2020-09-11
CN107406419A8 (zh) 2018-01-12
JP2018511648A (ja) 2018-04-26
JP2020158532A (ja) 2020-10-01
WO2016116875A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
JP6224063B2 (ja) ホスホジエステラーゼ１−標的トレーサーおよび方法
JP2016056184A5 (enExample)
EP2411057B1 (en) Imaging agents for detecting neurological disorders
JP7752201B2 (ja) 放射性標識カンナビノイド受容体２リガンド
TW200804363A (en) Novel radioligands
EP4028402A1 (en) Radiolabeled compounds
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
US10865195B2 (en) Pet imaging agents
WO2008024829A2 (en) Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers
Sai et al. Development of 18F-labeled PET probes for imaging cell proliferation
Pichika et al. Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3, 4-dehydropyrrolinyl methoxy)-5-(3′-18F-fluoropropyl) pyridine (18F-Nifrolene) using PET
JP6609868B2 (ja) 放射性ハロゲン標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物
JP7341139B2 (ja) イメージング剤
JP6709552B2 (ja) 核医学画像診断薬
Mao Design and synthesis of small molecule ligands targeting protease-activated receptor 2 as potential diagnostic and therapeutic agents
Cheng Towards synthesis and characterisation of [18F] DPA-714 for positron emission tomography imaging of the 18-kDa translocator protein (TSPO) in the brain

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted